Very exciting data from IBD Mount Sinai, in New York

Our #SARSCoV2 seroprevalence data published in Gut Journal Maintenance IFX & VDZ therapy in #IBD is not assoc. with increased seroprevalence. 1️⃣UK data & 1️⃣data from a paediatric IBD cohort. More data keenly anticipated from CLARITY IBD & ICARUS-IBD gut.bmj.com/content/early/…

Thank you very much to our collaborators around the world who are working very hard on ICARUS-IBD!

A brief introduction to our study can be found here! reports.mountsinai.org/article/gi2021…

Review highlighting need for large-scale, international trials to understand natural infection and vaccination responses in #IBD, and get better immunological insights! Helmsley Charitable Trust CLARITY IBD IOIBD Judith Wellens Jean-Frederic Colombel academic.oup.com/ecco-jcc/advan…

Proud of our team's hard work to present the first data to-date on COVID vaccines in IBD patients. Serological response to COVID-19 vaccination in IBD patients receiving biologics medrxiv.org/content/10.110…

Proud to present the first data on serological response to mRNA COVID vaccines in IBD patients: gastrojournal.org/article/S0016-…

Keep an eye on our website for the latest updates on the ICARUS-IBD Study! We have recruited 3085 participants from around the globe and our goal is 5000 🤞icarusibd.org

SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy thelancet.com/journals/langa…

Published in The Lancet Gastroenterology and Hepatology - April 2022 - Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease. thelancet.com/journals/langa…

Just arrived home from #DDW2022. It was great to have the opportunity to present some of the work of ICARUS-IBD—all a massive team effort with colleagues Judith Wellens Craig Thompson, and many more.